Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Spyre Therapeutics

08/05/2025 21:55

Spyre Therapeutics Inc SYRE.OQ reported a quarterly adjusted loss of 60 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.20.  The mean expectation of ten analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from $-1.06 to -49 cents per share.

Reported revenue was zero​; analysts expected zero.

Spyre Therapeutics Inc's reported EPS for the quarter was a loss of 60 cents​.

The company reported a quarterly loss of $44.77 million.

Spyre Therapeutics Inc shares had fallen by 21.2% this quarter and lost 45.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 5.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Spyre Therapeutics Inc is $65.00

This summary was machine generated from LSEG data May 8 at 08:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.84
-0.60
Beat
Dec. 31 2024
-0.99
-0.81
Beat
Sep. 30 2024
-0.82
-1.36
Missed
Jun. 30 2024
-0.95
-0.86
Beat